ROS1-positive non-small cell lung cancer (NSCLC)

Clinical trials for ROS1-positive non-small cell lung cancer (NSCLC) explained in plain language.

Never miss a new study

Get alerted when new ROS1-positive non-small cell lung cancer (NSCLC) trials appear

Sign up with your email to follow new studies for ROS1-positive non-small cell lung cancer (NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1 Not yet finished but already full! 1

Last-Resort drug access for rare lung cancer patients

Disease control Expanded access (ended)

This program provides taletrectinib, a targeted cancer pill, to adults with advanced or metastatic ROS1-positive non-small cell lung cancer who cannot join a clinical trial or use approved treatments. Patients must have a ROS1 gene fusion and adequate organ function. The goal is …

Matched conditions: ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)

Sponsor: Nuvation Bio Inc. • Aim: Disease control

Last updated Jun 27, 2026 08:07 UTC

ROS1-positive non-small cell lung cancer (NSCLC)

Get alerted when new ROS1-positive non-small cell lung cancer (NSCLC) trials appear

Last-Resort drug access for rare lung cancer patients